Sareum Collaborates with Almirall Prodesfarma
News Aug 10, 2005
Sareum Holdings plc has announced that it has entered into a collaborative agreement with Almirall Prodesfarma S.A., to provide protein structure determination capabilities to accelerate drug discovery research at Almirall.
Sareum will utilise its skills in high throughput protein expression, purification and structure determination with the aim of illustrating the precise nature of how Almirall's potential drug candidates interact with their target proteins.
This information will assist Almirall's scientists in their design of new and improved therapeutics against inflammatory diseases.
Sareum's Chief Executive Officer, Dr Tim Mitchell, said: "We are delighted that Almirall has chosen Sareum as their partner in protein structure determination."
He adds, "This is a further important collaboration that Sareum has signed since we started trading on AIM. We look forward to successful delivery of this project to Almirall and to closing additional partnerships such as this."
Almiralls's General Director for Research & Development, Dr José M Palacios, said: "We consider protein structure determination as an essential element in a modern drug discovery strategy, and we have high expectations that this collaboration with Sareum will allow Almirall to significantly leverage its drug discovery capacity."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018